News

The last 12 months collaboration allowed Bavarian Nordic to produce positive data, and to demonstrate that its recombinant vaccines platform, MVA-BN, can be efficiently and consistently manufacture with

Study 105 is a Phase I three-way crossover study of a single-dose of ADX10059, to study potential interactions with proton-pump inhibitors and food. The primary objectives are pharmacokinetics,

The device is a derivative of the company’s approved AutoXpress platform that is used to volume reduce and collect stem cells from umbilical cord blood. William Osgood, CEO

The randomized, double-blind, placebo-controlled Phase I trial will enroll 18 healthy volunteers at a single center in the US. The trial is designed to evaluate the compound’s safety

The submission package is based on a robust clinical development program consisting of five active or placebo-controlled Phase III trials assessing the efficacy and safety of Symbicort pressurized

Matrix has filed an abbreviated new drug application with the FDA seeking to market a generic version of Azor. Daiichi Sankyo and Daiichi Sankyo, Inc intend to vigorously

The current round of funding was led by the Psilos Group and CMEA Ventures, with participation by vSpring Capital, EPIC Ventures, The Dow Chemical Company, and the Southern

The company has also announced that Fred Colen will become the president of its Cardiac Rhythm Management (CRM) group, and that Paul LaViolette, COO, will be retiring from

Oxford BioMedica has completed four Phase II trials of TroVax in metastatic renal cancer in a total of 88 patients to evaluate the safety, immunogenicity and efficacy of